HONG KONG SAR - Media OutReach Newswire - 30 October 2024 - AIM Vaccine (06660.HK), the leader in Chinese mRNA vaccines, announced on 30th October that mRNA respiratory syncytial virus (RSV) vaccine developed by a controlled subsidiary of the Group , has been recently obtained from the National Medical Products Administration, which marks a new progress of the research and development of the vaccine.
Managed IT support is a comprehensive, subscription model approach to running and protecting your ...
How do you translate ancient Palmyrene script from a Roman tombstone? How many paired tendons ...
Today, many Australian businesses rely on cloud accounting platforms to manage their finances. Bec...
“Allergic disease” and eczema cases are spiking due to the current freak weather as the Bureau o...
By 2026, business communication is no longer just about making and receiving calls. It’s about speed...
This week, US President Donald Trump approved previously banned exports[1] of Nvidia’s powerful ...
Retirees need credible alternatives to downsizing that respect their preferences The national con...
Everyday Australians are struggling to make ends meet, with the cost-of-living crisis the major ca...
Federal Parliament returned this week to a familiar rhythm: government ministers defending the p...
Many Australian homeowners complain that their home is still missing something, even though they hav...
When the Reserve Bank of Australia (RBA) board voted unanimously[1] to lift the cash rate to 3.8...
Many buyers assume that a brand-new home does not need an inspection. After all, everything is new...
Planning an office relocation can be a complex task, especially when business operations need to con...
Gold and silver don’t usually move like meme stocks. They grind. They trend. They react to inflati...
The State of Play with the National Party and How Things Stand with the Liberal Party Australia’s...